The FDA expanded Repatha's label to include adults at increased risk for MACE due to uncontrolled LDL-C, broadening access beyond those with diagnosed CVD. Repatha is now approved as a standalone ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

The other half received the same aggressive cholesterol-lowering treatment, but their injections contained Repatha. After 48 weeks, their LDL cholesterol had dropped to unprecedented low levels (the ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...

The US Food and Drug Administration (FDA) has approved Amgen's cholesterol-lowering medication, Repatha (evolocumab) injection, a human monoclonal antibody that inhibits proprotein convertase ...

Cost watchdog the National Institute for Health and Care Excellence has turned down Amgen’s Repatha - the world’s first approved PCSK9 inhibitor - as an option for people with high cholesterol and ...

Patients receiving Repatha achieved a median LDL cholesterol level of 45 mg/dL compared to 109 mg/dL in the placebo group. "Repatha has once again demonstrated its ability to protect patients from the ...